Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Lenvatinib in advanced NSCLC (LEAP-007)
NCT04676412Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Oct 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04676412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676412.